Capricor Therapeutics, Inc. (NASDAQ:CAPR) belongs to Healthcare sector. Its weekly performance is -2.50%. On last trading day company shares ended up $4.68. Capricor Therapeutics, Inc. (NASDAQ:CAPR) distance from 50-day simple moving average (SMA50) is -22.39%. On 17 June, Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced the appointment of Houman Hemmati, M.D., Ph.D. to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor’s exosome platform into clinical development as he works closely with the R&D, manufacturing and product development teams.
5 days ago
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
December 16, 2021
Innocan announces the execution of a research & license agreement with Ramot, the technology transfer company of the Tel Aviv University for cannabinoids loaded exosome delivery platform (clx)
December 10, 2021